Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
复制标题
DOI：
10.1038/eye.2013.107
复制
发表时间：
2013-07-01
期刊：
影响因子：
3.9
通讯作者：
Nguyen, Q. D.
中科院分区：
文献类型：
--
作者：
Falavarjani, K. Ghasemi;Nguyen, Q. D.
玻璃体内注射抗血管内皮生长因子（VEGF）药物越来越多地用于各种视网膜疾病的治疗，包括年龄相关性黄斑变性、糖尿病视网膜病变和视网膜血管闭塞以及早产儿视网膜病变。尽管在阻止疾病和改善视力方面取得了令人鼓舞的结果，但玻璃体内注射抗vegf药物可能与全身不良事件和破坏性眼部并发症有关。在这篇综述中，我们提供了玻璃体内注射常用抗vegf药物的安全性数据概述。
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.